Thiopurine methyltransferase (TPMT) catalyses the Smethylation in azathioprine (AZA), thioguanine and 6-mercaptopurine (6-MP).
Genetic polymorphism of the TPMT activity in human was first reported by Weinshilboum and Sladek. 7) Four variant TPMT alleles, TPMT*2 (G238C), TPMT*3A (G460A, A719G), TPMT*3B (G460A) and TPMT*3C (A719G), were detected in over 80% of Caucasian individuals with intermediate metabolizers or poor metabolizers. 8) The TPMT activity of one subject with TPMT*1/*3C was 40% lower than the mean value of TPMT activities in 44 Japanese subject. 9) In the yeast expression system, TPMT activities of TPMT*2, TPMT*3A, TPMT*3B and TPMT*3C mutant alleles showed 1.4-100 fold lower than that with the wild-type, respectively. 10, 11) These results suggested that the genetic polymorphism is a major determinant of the TPMT activity.
On the other hand, Decaux et al. 12) measured significantly lower TPMT activity in 53 women with SLE when compared with 30 healthy control participants but not with 28 patients with other dysimmune diseases. The allele frequency of TPMT mutation in SLE patients however, have not been reported in any of the TPMT pharmacogenetic studies.
Based upon the background knowledge as discussed above, we intended to assess the genotype status of TPMT in a group of Japanese SLE patients who may undergo a therapy of AZA, a substrate drug, toward TPMT.
MATERIALS AND METHODS

DNA Samples
All of the study subjects included herein were Japanese by birth and lineage. The demographic characteristics of the subjects are summarized in Table 1 . The study samples consisted of 68 patients with SLE in Gunma University Hospital (men : womenϭ7 : 61) and 174 healthy volunteer subjects (men : womenϭ98 : 76). All subjects in the SLE group fulfilled 1982 revised criteria of American Rheumatology Association for the classification of SLE. 13) DNA analysis was approved by the institutional review board for clinical trials at Gunma University Hospital. Written informed consent was obtained from each participant after being informed of the experimental procedure and the purpose of the study. DNA reference samples with TPMT*1/*2 and TPMT*3A/*3A were kindly provided by Dr. Richard Weinshilboum, Mayo Medical School (Rochester), and TPMT*2/*2 and TPMT*1/*3A were provided by Dr. William Evans, St. Jude Children's Hospital (Memphis).
Determination of TPMT Genotype Genomic DNA was extracted from whole blood using a QIAamp ® Blood Kit (QIAGEN, U.S.A.). DNA was resuspended in 100 ml of TE buffer (10 mM Tris, 1 mM ethylenediamine tetraacetic acid, pH 8.0) and stored at 4°C.
The presence of G460A (TPMT*3A and TPMT*3B), A719G (TPMT*3A and TPMT*3C) and G238C (TPMT*2) mutations was detected according to the method of Yates et al. 8) with minor modifications. In brief, the amplification reaction was carried out in a total volume of 50 ml in the presence of 100 ng of DNA, 50 mM Tris-HCl (pH 8. We investigated the genotypic status of thiopurine methyltransferase (TPMT) polymorphism to evaluate the possible risk of the toxicity of azathioprine (AZA) in 68 patients with systemic lupus erythematosus (SLE). The allele frequency of TPMT mutation in the SLE group (2.9%) was higher than that in 174 Japanese healthy volunteers (1.1%), although it did not reach statistically significant difference (p‫.)32.0؍‬ The mean value of TPMT activities in 51 subjects with TPMT*1/*1 was 40% higher than that of 4 subjects with TPMT*1/*3C in SLE group (18.1؎6.1 nmol/h/ml packed red blood cells (pRBC) versus 13.2؎3.2 nmol/h/ml pRBC; p‫.)11.0؍‬ Two out of 4 SLE patients with TPMT*1/*3C had been treated with AZA, and one patient showed a leucopenia. The TPMT genotyping before AZA treatment is recommended for Japanese SLE patient group to avoid the AZA-induced adverse events, although detection of the patient with low TPMT activity by genotyping is still imperfect.
Key words thiopurine methyltransferase; systemic lupus erythematosus; pharmacogenetics Biosystems, U.S.A.). The PCR products were digested with Mwo I at 60°C for 2 h (G460A) or Acc I at 37°C for 2 h (A719G), and the DNA fragments were separated on 2.5% agarose gel. The G238C mutation (TPMT*2) was analyzed using an allele specific PCR. 8) DNA fragment was amplified in the presence of 100 ng of genomic DNA, 50 mM Tris-HCl (pH 8.3), 50 mM KCl, 3.5 mM MgCl 2 , 0.01% (w/v) gelatin, 0.5 mM each primer and 1U AmpliTaq Gold TM DNA polymerase. The PCR protocol was the same as described for the detection of G460A mutation. The DNA fragments were separated on 2.5% agarose gel.
Determination of TPMT Activity Venous blood samples were collected from 55 patients with SLE. Red cells were prepared as described previously. 14) Briefly, 5 ml of whole blood collected in heparinized tubes was centrifuged at 800 g for 10 min at 4°C to isolate red cells. After washing the pellet twice with 3 ml of normal saline and centrifuged at 800 g, cells were gently resuspended in 2 ml of saline and the haematocrit was determined. After this step, the results of the assay can be expressed in terms of milliliters of packed red blood cells (pRBC). Red cells were lysed with cold distilled water (4 ml for 1 ml of solution) and centrifuged (13000 g, 10 min, 4°C). The supernatant was kept at Ϫ80°C until analysis. TPMT is stable for several months under these conditions.
TPMT activity was determined by measuring the 6-methyl mercaptopurine (6-MMP) formed in the enzymatic reaction. The assay was performed as previously described 15) with minor modifications. The assay has been performed in a total volume of 600 ml. The final concentrations of 6-MP, S-adenosyl-L-methionine, dithiothreitol (DTT) and alloprinol were 3 mmol/l, 25 mmol/l, 5 mmol/l and 25 mmol/l, respectively. The reaction was stopped after 1.5 h by addition of hydrochloric acid (1 M) 100 ml.
After incubation phase, a liquid-liquid extraction was performed as previously described. 16) Procedures of HPLC were similar to those previously described.
17) The analytical column was a Tosoh TSK-GEL, ODS-80Tm (250ϫ4.6 mm), the mobile phase of water-acetonitrile-triethylamine-DTT (92.7 : 7 : 0.2 : 0.1, v/v) was adjusted to pH 3.2 with orthophosphoric acid and pumped at a flow-rate of 1.0 ml/min. The detection wavelength was 290 nm.
The enzyme activity was expressed as international units (nmol 6-MMP formed per hour) per milliliter of pRBC.
Statistical Analysis The statistical significance of the differences in genotype between the two populations was determined using Fisher's exact test.
RESULTS
Heterozygote (TPMT*3C) individuals were detected in 4 of the SLE group (nϭ68) and 4 of the control group (nϭ174). Neither G238C nor G460A mutation was detected in any subject enrolled in this study. Among the 68 patients in the SLE group, the allele frequencies of TPMT*2, TPMT*3A, TPMT*3B and TPMT*3C were 0, 0, 0 and 2.9%, respectively ( Table 2 ). The allele frequency of TPMT mutation in the SLE group was greater than that (1.1%) of the healthy control in this study and any other reported value in Japanese healthy subjects. [18] [19] [20] In the present study, mean value of TPMT activities in 51 subjects with TPMT*1/*1 (18.1Ϯ6.1 nmol/h/ml pRBC) was 40% higher than that of 4 subjects with TPMT*1/*3C (13.2Ϯ3.2 nmol/h/ml pRBC) (Fig. 1A) . Ten patients with TPMT*1/*1 showed lower TPMT activity than the mean value in patients with TPMT*1/*3C. Therefore, detection of the patients with low TPMT activity only by genotyping of TPMT is still imperfect.
Though the majority of our patients tolerated azathioprine well, azathioprine was withdrawn in a small number of patients because of leucopenia (nϭ3, Fig. 1B) . Two out of 4 SLE patients with heterozygous TPMT*3C had been treated with AZA, and one patient showed a leucopenia (WBC 2300/mm 3 ) after a 1-month AZA (50 mg/d) therapy.
DISCUSSION
This report is, to our knowledge, the first to document the allele frequency and the enzymatic activity of TPMT in SLE patients, a candidate patient group who may undergo an AZA therapy.
Since the allele frequency of TPMT*3C did not reach a statistically significant difference between the SLE patient and healthy control groups (pϭ0.23), we estimated a betaerror (or beta-power) of our study according to a chi-square test. 21, 22) If we decide to reject null hypothesis at a two-sided alpha-level of 0.05 with beta-level of 0.2, the total number of the study subjects needed for a proposed research would be 546 (Ͼ1091/2) for both the SLE and control groups. This was a difficult task for the proposed research, because such a 2118
Vol. 28, No. 11 large number of SLE patients could not be collected at our hospital. With this limitation in the study, the observed trend that the TPMT*3C allelic frequency (2.9%) was greater in the SLE patient group compared with that (1.1%) in the control group may be a chance observation.
Naughton et al. 23) determined TPMT genotype in 120 patients with SLE in United Kingdom, and found one homozygote and five heterozygotes with TPMT*3A allele, and one heterozygote of TPMT*3C. A patient with homozygous TPMT*3A allele in whom rapid bone marrow aplasia developed by AZA. Additionally, three heterozygotes had shown an excellent disease control by subtherapeutic dose of AZA (25-150 mg/d). In the yeast expression system, the TPMT activities of TPMT*2, TPMT*3A, TPMT*3B and TPMT*3C mutant alleles showed Ͼ100-fold, Ͼ100-fold, 9-fold and 1.4-fold lower than that with the wild-type, respectively. 10, 11) When expressed in humans, the immunodetectable TPMT protein in TPMT*3C heterozygous individuals was about 50% lower than in homozygous wild-type individuals.
24) The TPMT activity of one subject with TPMT*1/*3C was 40% lower than the mean value of TPMT activities in 44 Japanese subject. 9) In the present study, the TPMT activity of subjects with TPMT*1/*3C (nϭ4; men: 2, women: 2) was 30% lower than that of subjects with TPMT*1/*1 (nϭ51; men: 5, women: 46) (Fig. 1A) . This result was consistent with the previous reports.
In our study, two out of 4 SLE patients with heterozygous TPMT*3C had been treated with AZA, and one patient showed a leucopenia (WBC 2300/mm 3 ) after a 1-month AZA (50 mg/d) therapy, suggesting the likeliness that the TPMT pharmacogenetic assessment may be an important clinical tool for predicting an AZA-related toxicity. On the other hand, two patients with homozygous TPMT*1 showed hematopoetic toxicity, and TPMT activity of these patients is similar to that of TPMT*3C heterozygous (Fig. 1B) . Since there is probably a variety of reasons of low TPMT activity and/or development of thiopurine toxicity, careful monitoring should be continued for the patients with wild type TPMT gene. 25) In conclusion, the allele frequency of TPMT mutation in the Japanese SLE patient group was 2.9%. The TPMT genotyping may be useful for Japanese SLE patient group to avoid the AZA-induced adverse events, although detection of the patient with low TPMT activity only by genotyping is still imperfect.
